<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5173-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESOPEROL 40MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ESOPEROL contains a medicine called esomeprazole. This belongs to a group of medicines called</p><p>&lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p>&nbsp;</p><p>ESOPEROL is presented in vials containing 40 mg esomeprazole powder.</p><p>ESOPEROL is used for the short-term treatment of certain conditions, when you are unable to have treatment by mouth.&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;Adults</u>&nbsp; &bull; &lsquo;Gastroesophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). ESOPEROL can also be used to stop stomach ulcers from forming if you are taking NSAIDs.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.&nbsp;</p><p>&nbsp;</p><p><u>Children and adolescents aged 1-18 years</u>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;Gastroesophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use ESOPEROL</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are hypersensitive to esomeprazole or any of the other ingredients of ESOPEROL (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole, rabeprazole, omeprazole).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As with other proton pump inhibitors, esomeprazole should not be used together with atanazavir or nelfinavir [used to treat HIV (AIDS)].</p><p>&nbsp;</p><p>You must not be given ESOPEROL if any of the above apply to you. If you are not sure, talk to your doctor or nurse before you are given this medicine.</p><p>&nbsp;</p><p>b. Take special care with ESOPEROL</p><p>Talk with your doctor or nurse before taking ESOPEROL or during your therapy, for following cases:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice any of the following:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &minus; &nbsp;&nbsp; You have severe liver problems.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &minus; &nbsp;&nbsp; You have severe kidney problems.</p><p>&minus; You have ever had a skin reaction after treatment with a medicine similar to ESOPEROL that reduces stomach acid.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &minus; &nbsp;&nbsp; You are due to have a specific blood test (Chromogranin A).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ESOPEROL may hide the symptoms of other diseases. <strong>Therefore, if any of the following happen to you before you are given ESOPEROL or after you are given it, talk to your doctor straight away: </strong></p><p>&minus; You lose a lot of weight for no reason and have problems swallowing.</p><p>&minus; You get stomach pain or indigestion.&nbsp;</p><p>&minus; You begin to vomit food or blood.&nbsp;</p><p>&minus; You pass black stools (blood-stained faeces).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking a proton pump inhibitor like ESOPEROL, especially over a period of more than one year, may slightly increase the risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis (bone loss) or if you using corticosteroids (may increase the risk of osteoporosis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with ESOPEROL. Remember to also mention any other ill effects like pain in your joints.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in blood magnesium levels (hypomagnesaemia) has been reported. If you are to receive a long-term treatment, or if you need to use proton pump inhibitors together with drugs such as digoxin or with drugs which may cause decreased blood magnesium levels (e.g. diuretics), your doctor may consider monitoring blood magnesium levels before initiation of your treatment and later periodically.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interactions with investigations for endocrine gland (neuroendocrine) tumors: false positive results in tumor diagnosis associated with the neural system and the endocrine glands may be gained due to drug-induced decrease in gastric acid levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal system infections.</p><p>&nbsp;</p><p>If these warnings are valid for you, even for a period in the past, please consult your doctor.</p><p>&nbsp;</p><p>c. Taking/using other medicines</p><p>If ESOPEROL is used together with the medicines listed below, it may affect the way of working or some of the medicines may have an effect on ESOPEROL.</p><p>&nbsp;</p><p>Do not use ESOPEROL if you are using drugs containing nelfinavir or atazanavir (used in AIDS treatment).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clopidogrel (used to prevent blood clots).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erlotinib (used to treat cancer).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Citalopram, imipramine or clomipramine (used to treat depression).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop having ESOPEROL.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop having ESOPEROL.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cilostazol (used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride (used for indigestion and heartburn).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin (used for heart problems).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are using high dose of methotrexate, your doctor may temporarily stop your ESOPEROL treatment.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus (organ transplantation).&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used for treatment of tuberculosis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort <em>(Hypericum perforatum) </em>(used to treat depression).</p><p>&nbsp;</p><p>If you are prescribed ESOPEROL together with amoxicillin and clarithromycin to treat ulcer caused by <em>Helicobacter pylori</em>, it is very important that you inform you doctor of any other drug you are using.</p><p>&nbsp;</p><p><em>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</em></p><p>&nbsp;</p><p><strong>d.</strong><strong> Using ESOPEROL with food and drink </strong></p><p>There is no interaction with food or drink because of its administration method.</p><p>&nbsp;</p><p>&nbsp;</p><p>e. &nbsp;Pregnancy and breast-feeding</p><p>&nbsp;</p><p><u>Pregnancy:</u></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine. Your doctor will decide whether you can take ESOPEROL during this time.</p><p>&nbsp;</p><p><u>Breast-feeding:</u></p><p>It is not known if ESOPEROL passes into breast milk. Therefore, you should not be given ESOPEROL if you are breastfeeding.</p><p>&nbsp;</p><p><em>Ask your doctor or pharmacist for advice before taking any medicine. </em></p><p><em>&nbsp;</em></p><p>f. Driving and using machines</p><p>ESOPEROL is not likely to affect you being able to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly occur (see section 4). If affected, you should not drive or use machines.&nbsp;</p><p>&nbsp;</p><p>g. Important information about some of the ingredients of ESOPEROL</p><p>No negative effect is to be expected, if you don&rsquo;t have hypersensitivity against any of the excipients in ESOPEROL.</p><p>&nbsp;</p><p>Each vial contains less than 1 mmol (23 mg) sodium. No side effects are to be expected in this dose for sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use ESOPEROL exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure.</em><strong> </strong></p><p>&nbsp;</p><p>ESOPEROL can be given to children and adolescents aged 1-18 years and adults, including the elderly.</p><p>&nbsp;</p><p><strong>Being given ESOPEROL </strong></p><p><em><u>Use in adults</u> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ESOPEROL will be given to you by your doctor who will decide how much you need.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 20 mg or 40 mg once a day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, the maximum dose is 20 mg a day (GERD).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine will be given to you as an injection or infusion into one of your veins. This will last for up to 30 minutes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose for prevention of re-bleeding of gastric or duodenal ulcer, is 80 mg administered as intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg/hr given over 3 days. If you have severe liver problems, a continuous infusion of 4 mg/hr given over 3 days may be sufficient.</p><p><strong>&nbsp;</strong></p><p><em><u>Use in children and adolescents</u> </em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ESOPEROL will be given by your doctor who will decide how much you need.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children 1-11 years, the usual dose is 10 or 20 mg given once a day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children 12-18 years, the usual dose is 20 or 40 mg given once a day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine will be given as an injection or infusion into a vein. This should be administered for at most 30 minutes.</p><p>&nbsp;</p><p><strong>Use in elderly: </strong>ESOPEROL can be used in elderly.</p><p>&nbsp;</p><p><strong>Special conditions for use </strong></p><p><strong>&nbsp;</strong></p><p>Liver insufficiency</p><p>In patients with mild to moderate liver insufficiency the breakdown of esomeprazole may be impaired. In patients with severe liver insufficiency the breakdown of the medicine decrease and the blood levels may increase. Therefore for patients with severe liver insufficiency, daily dose of 20 mg should not be exceeded. Esomeprazole or the breakdown products have no tendency for accumulation during once daily administration.</p><p>&nbsp;</p><p>Kidney insufficiency</p><p>There is no study in patients with kidney insufficiency. Change in breakdown rate of esomeprazole is not expected in patients with kidney insufficiency.</p><p>&nbsp;</p><p><em>If you have the impression that the effect of ESOPEROL is too strong or too weak, please contact your doctor or pharmacist.</em></p><p><em>&nbsp;</em></p><p>a. If you take more ESOPEROL than you should</p><p>If you suspect that you are given more ESOPEROL than you should receive, you may encounter some of the side effects listed below, please inform you doctor.</p><p>&nbsp;</p><p><em>If you have used too much ESOPEROL than you should talk to your doctor or nurse. </em></p><p>&nbsp;</p><p>b. If you forget to take ESOPEROL</p><p><em>Do not take a double dose to make-up for a forgotten dose. </em></p><p><em>&nbsp;</em></p><p>c. If you stop taking ESOPEROL</p><p>Your doctor will tell you how long your treatment with ESOPEROL will take. Do not stop your treatment early, because the symptoms of your illness may return, or may exacerbate.</p><p>&nbsp;</p><p><em>If you have any further questions on the use of this product, ask your doctor, nurse or health care provider or pharmacist. </em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Serious side effects</p><p><strong>&nbsp;</strong></p><p><strong>If you experience any of the following, stop using ESOPEROL and tell your doctor IMMEDIATELY or contact the emergency department at the nearest hospital to you: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems concurrently.</p><p>&nbsp;</p><p>These effects are rare, and may affect up to 1 in 1000 people.</p><p>&nbsp;</p><p>If you have any of these, it means you have a serious allergy to ESOPEROL. You may need emergency medical attention or to be hospitalized.</p><p>&nbsp;</p><p>&nbsp;</p><p>Possible Side Effects</p><p>&nbsp;</p><p>Like all medicines, ESOPEROL can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Other side effects include:&nbsp;</p><p>&bull;&nbsp; <strong>Common (may affect up to 1 in 10 people)</strong> &minus; Headache.</p><p>&minus; Effects on your stomach or gut: diarrhea, abdominal pain, constipation, wind (flatulence).</p><p>&minus; Feeling sick (nausea) or being sick (vomiting).</p><p>&minus; Injection site reactions.</p><p>&minus; Benign polyps in the stomach.</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp; <strong>Uncommon (may affect up to 1 in 100 people) </strong>&minus; Swelling of the feet and ankles. &minus; Sleep disorders (insomnia).</p><p>&minus; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy. &minus; Spinning feeling (vertigo).</p><p>&minus; Eyesight problems such as blurred vision.&nbsp;</p><p>&minus; Dry mouth.</p><p>&minus; Changes in blood tests that check how the liver is working.</p><p>&minus; Skin rash, lumpy rash (hives) and itchy skin.</p><p>&minus; Fracture of the hip, wrist or spine (if ESOPEROL is used in high doses and over long duration).</p><p><strong>&nbsp;</strong></p><p>&bull; Rare (may affect up to 1 in 1,000 people)</p><p>&minus; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>&minus; Low levels of sodium in the blood. This may cause weakness, feeling sick (vomiting) and cramps.</p><p>&minus; Feeling agitated, confused or depressed.</p><p>&minus; Taste changes.</p><p>&minus; Suddenly feeling wheezy or shortness of breath (bronchospasm). &minus; An inflammation of inside of the mouth.</p><p>&minus; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>&minus; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness. &minus; Hair loss (alopecia).</p><p>&minus; Skin rash on exposure to sunshine.</p><p>&minus; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&minus; Generally feeling unwell and lacking energy.</p><p>&minus; Increased sweating.</p><p>&nbsp;</p><p>&bull; Very rare (may affect up to 1 in 10,000 people)</p><p>&minus; Changes in blood count including agranulocytosis (lack of white blood cells).</p><p>&minus; Aggression.</p><p>&minus; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>&minus; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>&minus; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>&minus; Muscle weakness.</p><p>&minus; Severe kidney problems.</p><p>&minus; Enlarged breasts in men.</p><p>&nbsp;</p><p>&bull; <strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&minus; If you are on ESOPEROL for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.&nbsp;</p><p>&minus; Inflammation in the gut (leading to diarrhoea).&nbsp;</p><p>&minus; Rash, possibly with pain in the joints.&nbsp;</p><p>&nbsp;</p><p>ESOPEROL may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a <strong>severely </strong>reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time.</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</em></p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use ESOPEROL after the expiry date which is stated on the carton or vial. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C. Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Do not use ESOPEROL if you notice any defect in the product and/or on its packaging.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong><em>Active Substance: </em></strong>Each vial contains 42.5 mg esomeprazole sodium equivalent to 40 mg esomeprazole.</p><p><strong><em>Excipient(s): </em></strong>Disodium edetate dehydrate, sodium hydroxide (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ESOPEROL is Powder for Solution for IV Injection/Infusion containing 40 mg esomeprazole. ESOPEROL is white to pale yellow colored freeze-dried mass in a colorless glass vial sealed with rubber stopper and flip-off aluminum cap. 
One vial is inserted into printed carton, together with its leaflet. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong> Gensenta İla&ccedil; Sanayi ve Ticaret A.Ş. İş Kuleleri, Levent Mah., Meltem Sok.&nbsp; No: 10 Kule: 2 Kat: 24&nbsp;</p><p>4. Levent, Beşiktaş &ndash; Istanbul/TURKEY</p><p>Tel : +90.212.337 38 00 Fax : +90.212.337 38 01</p><p>e-mail : info@gensenta.com.tr</p><p>&nbsp;</p><p>Manufacturer</p><p>Gensenta İla&ccedil; Sanayi ve Ticaret A.Ş.&nbsp;</p><p>Sanayi Cad. No: 13</p><p>Yenibosna, Bah&ccedil;elievler &ndash; Istanbul/TURKEY</p><p>Tel: +90 212 454 76 00</p><p>Fax: +90 212 454 76 96</p><p>e-mail: info@gensenta.com.tr</p><p>&nbsp;</p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</em> Kingdom of Saudi Arabia Salehiya Trading Co.</p><p>P.O. Box: 991 Riyadh: 11421</p><p>Tel. No.: +966 11 464 6955</p><p>Fax No.: +966 11 463 4362</p><p>Website: www.salehiya.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2020; version number 04 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>ما هو إيزوبيرو ل</strong><strong> </strong><strong>وما هي استخداماته </strong></p><p dir="RTL">يحتوي إيزوبيرول على دواء يدعى إيزوميبرازول .ينتمي لمجموعة أدوية تدعى&quot; مثبطات مضخة بروتون .&quot;يعمل عن طريق تقليل كمية الحمض التي تنتجها معدتك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يقدم إيزوبيرول في قارورات تحتوي على 40 ملغم مسحوق إيزوميبرازول.</p><p dir="RTL">يستخدم إيزوبيرول للعلاج قصير الأمد في حالات معينة، عند عد م قدرتك على تناول العلاج عن طريق الفم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>البالغين</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; &rsquo;مرض الإرتداد المعدي المريئي&lsquo; )غيرد( .يعود هذا عندما ينتقل الحمض من المعدة إلى المريء ) الأنبوب الذي يصل حلقك بمعدتك( مما يسبب الألم، الالتهاب و حرقة في المعدة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; &nbsp;&bull;تقرحات المعدة نتيجة أدوية تسمى) أدوية مضادة للإلتهاب غير ستيرودية( NSAIDs. يمكن أن يستخدم إيزوبيرول ايضا لوقف تكوين تقرحات المعدة إذا كنت تتناول أدوية مضادة للإلتهاب غير ستيرودية .NSAIDs</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; الوقاية من عودة النزيف بعد التنظير العلاجي للنزيف المعوي الحاد أو تقرحات الإثنى عشر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>الأطفال و المراهقين التي تتراوح اعمارهم </u><u>1</u><u>-</u><u>18</u><u> سنة</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; &rsquo;مرض الإرتداد المعدي المريئي &lsquo;)جيرد( .يعود هذا عندما ينتقل الحمض من المعدة إلى المريء ) الأنبوب الذي يصل حلقك بمعدتك مما يسبب الألم، الالتهاب و حرقة في المعدة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:679px"><tbody><tr><td style="vertical-align:top"><p><strong>لا تستخدم إيزوبيرول</strong></p></td><td style="vertical-align:top"><p><strong>ا. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; إذا كانت لديك فرط حساسية تجاه إيزوميبرازول أو أي من المكونات الأخرى لإيزوبيرول&nbsp; ) المدرجة في البند6 ( .</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; إذا كانت لديك حساسية تجاه أدوية تثبيط مضخة البروتون الأخرى )مث ل بانتوبرازول، لانسوبرازول، رابيبرازول، أوميبرازول(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; كسائر مثبطات مضخة البروتون، يجب عدم استخدام إيزوميبرازول معا مع أتازانافير و نيلفينافير ]يستخدمون لعلاج نقص المناعة</p><p>&nbsp;[(AIDS) HIV المكتسب</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:679px"><tbody><tr><td style="vertical-align:top"><p>يجب عدم إعطائك إيزوبيرول إذا كان ينطبق عليك أي مما سبق .إذا لم تكن متأكد اً، استشر طبيبك أو الممرضة قبل أخذك لهذا الدواء.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>عامل مع إيزوبيرول بعناية خاصة </strong></p><p>تكلم مع طبيبك أو الممرضة قبل أخذ إيزوبيرول أو خلال العلاج، للحالات التالية:</p></td><td style="vertical-align:top"><p><strong>ب. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; اذا لاحظت أي من التالي:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; إذا كنت تعاني من مشاكل حادة في الكلى.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; إذا حصل لديك في اي وقت مضى ردة فعل جلدية بعد العلاج بدواء مشابه لإيزوبيرول والذي يعمل على خفض حمض المعدة.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>إذا كنت ستخضع لفحص دم معين )كروموغرانين آي(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; قد يخفي إيزوبيرول أعراض أمراض أخرى .<strong>لذلك، أذا حدث معك أي من التالي قبل اعطائك إيزوبيرول أو بعد ستخدامه، استشر طبيبك فور اً:</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; فقدت الكثير من الوزن من غير سبب و كان لديك مشاكل في البلع.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; كنت تعاني من آلام في المعدة أو عسر الهضم.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; بدأت بتقيؤ الطعام أو الدم.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; كان لديك براز أسود&nbsp; )براز مع بقع دم(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; &nbsp;&bull;أخذ مثبط مضخ ة البروتون مثل إيزوبيرول، خاصة على فترة تزيد عن السنة الواحدة، قد تزيد بشكل بسيط احتمال العرضة للكسر في الورك، الرسغ أو العمود الفقري .اخبر طبيبك إن كنت تعاني من هشاشة العظا م )فقدان العظم( أو إذا كنت تستخدم كورتيكوستيرويدات )قد تزيد احتمال العرضة لهشاشة العظام(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; &nbsp;&bull;إذا ظهر طفح جلدي على بشرتك،&nbsp; خاصة في المناطق المعرضة للشمس أخبر طبيبك بأسرع ما يمكن، فقد تحتاج لوقف العلاج&nbsp; بإيزوبيرول. لا تنسى ايضا أن تذكر أي آثار مرضية أخرى مثل ألم المفاصل.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; تم الإبلاغ عن انخفاض مستويات المغنيسوم في الدم )نقص مغنيسيوم الدم.( إذا كنت ستتلقى العلاج لفترة طويلة، أو إذا كنت تحتاج لاستخدام مثبطات مضخة البروتون مع اً مع أدوية مثل ديجوكسين أو مع أدوية قد تؤدي إلى انخفاض مستويات المغنيسوم في الدم )مثل مدرّات البول(، قد ينظر طبيبك في مراقبة مستويات مغنيسيوم الدم قبل البدء بعلاجك و لاحقا بشكل منتظم.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; تفاعلات في فحوصات لأورام الغدة الصماوية )العصبي الصماوي:(&nbsp; ق د تحصل نتائج إيجابية كاذبة في تشخيص الأورام المرتبطة بالجهاز العصبي و الغدد الصماوية الناجم عن انخفاض مستويات حم ض المعدي التي يسببها الدواء.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; انخفاض الحموضة المعدية بسبب أي وسيلة و يشمل ذلك مثبطات مضخة البروتون يؤدي لزيادة تعداد البكتيريا في المعدة والموجودة طبيعي اً في الجهاز الهضمي .العلاج باستخدام مثبطات مضخ ة البروتون قد يؤدي إلى زيادة طفيف ة في خطر العرضة لالتهابات معد ية معوية.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>إذا كانت هذه المحاذير تنطبق عليك، حتى ولو في فترة من الماضي، يرجى استشارة طبيبك.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>أخذ /استخدام أدوية أخرى</strong></p></td><td style="vertical-align:top"><p><strong>جـ.</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>إذا أخذ إيزوبيرول معا مع الأدوية المدرجة أدناه، قد يؤثر على كيفية العمل أو قد تؤثر بعض الأدوية على إيزوبيرول.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>لا تستخدم إيزوبيرول إذا كنت تأخذ أدوية تحتوي على نيلفينافير أو أتازانافير )يستخدمون لعلاج AIDS(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>اخبر طبيبك أو الصيدلي إذا كنت تأخذ أي من الأدوية التالية:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; كلوبيدوجريل ) يستخدم لمنع جلطات الدم(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; كيتوكونازول، إيتراكونازول أو فوريكونازول )يستخدمون لعلاج الالتهابات الناجمة عن الفطريات (.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; يرلوتينيب )يستخدم لعلاج السرطان(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيتالوبرام، إيميبرامين أو كلوميبرامين )يستخدمون لعلاج الاكتئاب(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; ديازيبام )يستخدم لعلاج القلق، استرخاء العضلات أو في الصرع(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; فينيتوين )يستخدم في الصرع( . إذا كنت تأخذ فينيتوين، سيحتاج طبيبك لمراقبتك عند بداية أو إيقاف أخذ إيزوبيرول.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; الأدوية التي تستخدم لترقيق دمك، مثل الوارفارين .قد يحتاج طبيبك لمراقبتك عند بداية أو إيقاف أخذ إيزوبيرول.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيلوستازو ل )يستخدم لعلا ج العرج المتقطع&ndash;ألم في ساقيك عند المشي الناتج عن إمداد دم غير كافي(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيسابرايد )يستخدم لعسر الهضم أو حرقة المعدة(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; ديجوكسين )يستخدم لمشاكل القلب(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; ميثوتريكسيت )دواء علاج كيماوي يستخدم بجرعات عالية لعلاج السرطان( &ndash; إذا كنت تستخدم جرعات عالية من ميثوتريكسيت، فقد يوقف طبيبك العلاج بإيزوبيرول مؤقتاً.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; تاكروليمس )زراعة الأعضاء(. &nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; ريفامبيسين )يستخدم لعلاج مرض السل(.&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; نبتة سانت جونز (<em>Hypericum perforatum</em>) )تستخدم لعلاج الاكتئاب(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>إذا وصف لك إيزوبيرول معا مع أموكسيسيلين و كلاريثروميسين لعلاج القرحة الناجمة عن <em>Helicobacter pylori</em>، من المهم أن تعلم طبيبك عن أي أدوية أخرى تستخدمها.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:679px"><tbody><tr><td style="vertical-align:top"><p>يرجى<em> </em>اخبار<em> </em>طبيبك<em> </em>أو<em> </em>الصيدلي<em> </em>في<em> </em>حال<em> </em>كنت<em> </em>تأخذ<em> </em>أو<em> </em>أخذت<em> </em>مؤخرا<em> </em>أية<em> </em>أدوية<em> </em>أخرى،<em> </em>بما<em> </em>في<em> </em>ذلك<em> </em>الأدوية<em> </em>التي<em> </em>تم<em> </em>الحصول<em> </em>عليها بدون<em> </em>وصفة<em> </em>طبية<em>.</em><em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>استخدام إيزوبيرول مع الطعام أو الشراب</strong></p></td><td style="vertical-align:top"><p><strong>د. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>لا يوجد تفاعل مع الطعام أو الشراب بسبب طريقة الاستخدام.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>الحمل و الرضاع ة</strong></p></td><td style="vertical-align:top"><p><strong>هـ.</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p><u>الحمل :</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>إذا كنت حامل، تعتقدين بأنك حامل أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي قب ل اعطائك هذا الدواء .سيقرر طبيبك اذا كان من الممكن ان تستخدمي إيزوبيرول خلال هذا الوقت.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>الرضاعة :</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>من غير المعروف إذا كان إيزوبيرول يمر إلى حليب الرضاعة .لذلك، يجب ألا يتم إعطائك إيزوبيرول إذا كنت ترضعين.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>استشيري<em> </em>طبيبك<em> </em>أو<em> </em>الصيدلي<em> </em>قبل<em> </em>استخدام<em> </em>أي<em> </em>دواء.<em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>القيادة واستخدام الآلات</strong></p></td><td style="vertical-align:top"><p><strong>و. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>من غير المرجح أن يؤثر إيزوبيرول على قدرتك على القيادة أو استخدام الأدوات او الآلات .و مع ذلك، أعراض جانبية مثل الدوخة و عدم وضوح الرؤية قد تحدث بشكل غير شائع )انظر البند4 (. إذا أحسست بالتأثر، فيجب عليك عدم القيادة أو استخدام الآلات.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>معلومات مهمة بشأن بعض مكونات إيزوبيرول </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>ز. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>لا يتوقع أي آثار سلبية إذا لم يكن لديك فرط الحساسية تجاه أي م ن السواغات في إيزوبيرول.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>تحتوي كل قارورة على أقل من 1 مل مول صوديوم ) 23 ملغم(. لا أعراض جانبية متوقعة لهذه الجرعة من الصوديوم. &nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:679px"><tbody><tr><td style="vertical-align:top"><p>يجب<em> </em>استخدم<em> </em>إيزوبيرول دائما<em> </em>كما<em> </em>أخبرك<em> </em>طبيبك<em> </em>أو<em> </em>مقدم<em> </em>الرعاية<em> </em>الصحية<em> </em>تماما.<em> .</em>يجب<em> </em>مراجعة<em> </em>طبيبك،<em> </em>مقدم<em> </em>الرعاية<em> </em>الصحية<em> </em>أو الصيدلي<em> </em>إن<em> </em>كنت<em> </em>غير<em> </em>متأكد<em>.</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>م ن الممك ن إعطاء إيزوبيرول للأطفال&nbsp; و المراهقي ن الت ي تتراوح اعمارهم 1-18 سنة&nbsp; و البالغين، بما في ذلك كبار الس ن.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>عند إعطائك إيزوبيرو ل</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>الإستخدام</u><em><u> </u></em><u>ف ي</u><em><u> </u></em><u>البالغين</u><em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيتم إعطاؤك إيزوبيرول م ن قبل طبيبك حي ث سيقرر الكمية الت ي ستحتاجها</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; الجرعة الموصى بها هي 20 ملغم أو 40 ملغم مرة واحدة يومياً .</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; إذا كن ت تعان ي م ن مشاكل حادة ف ي الكبد، فإ ن الجرعة القصوى ه ي 20 ملغم ف ي اليوم )غيرد(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيتم إعطاؤك الدواء كحقنة أ و عن طريق التشري ب ف ي أحد أوردتك. قد يستمر لمدة تصل ل 30 دقيقة.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; الجرعة الموصى بها للوقاية من عودة نزيف قرحة المعدة أو الإثنى عشر هي 80 ملغم يتم اعطاؤها كتشريب وريدي على مدى 30 دقيقة تليها تشريب مستمر من 8 ملغم/ساعة تعطى على مدى 3 أيام .إذا كنت تعاني من مشاكل حادة في الكبد، قد يكون تشريب مستمر من 4 ملغم /ساعة تعطى على مدى 3 أيام كافية.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>الإستخدام</u><em><u> </u></em><u>عند</u><em><u> </u></em><u>الأطفال</u><em><u> </u></em><u>و</u><em><u> </u></em><u>المراهقين</u><em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيتم إعطاؤك إيزوبيرول م ن قبل طبيبك حي ث سيقرر الكمية الت ي ستحتاجها.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; للأطفال الذين أعمارهم 1-11سنة، الجرعة المعتادة 10 أو 20 ملغم تؤخذ مرة واحد ة في اليوم.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; للأطفال الذين أعمارهم 12-18 سنة، الجرعة المعتادة 20 أو 40 ملغم تؤخذ مرة واحدة في اليوم.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&bull; سيتم إعطاء الدواء كحقنة أو تشري ب في الوريد .ويجب إعطاؤه على الأكثر ل 30 دقيقة.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>الاستخدام في كبار السن : </strong>من الممكن استخدام إيزوبيرول في كبار السن.</p><p>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>حالات خاصة للاستخدام</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>قصور الكبد</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>قد يكون هناك قصور في تحطم إيزوميبرازول في المرضى باعتلال الكبد الخفيف إلى المتوسط .يقل تحطم الدواء و قد تزيد</p><p>المستويات في الدم في المرضى باعتلال الكبد الشديد .لذا للمرض ى باعتلال الكبد الشديد يجب عدم تجاوز الجرعة اليومية 20 ملغم .لا توجد قابلية لتراكم إيزوميبرازول أو نتائج التحطم خلال الاستخدام الواحد يومياً.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>قصور الكلى</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>لا توجد دراسات في مرضى قصور الكلى .لا يتوقع حصول تغيير في تحطم إيزوميبرازول لدى مرضى قصور الكلى.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>إذا<em> </em>كان<em> </em>عندك<em> </em>الانطباع<em> </em>أن<em> </em>تأثير<em> </em>إيزوبيرول<em> </em>قوي<em> </em>جد اً<em> </em>أو<em> </em>ضعيف<em> </em>جداً،<em> </em>يرجى<em> </em>الاتصال<em> </em>بطبيبك<em> </em>او<em> </em>الصيدلي. <em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>إذا أخذت إيزوبيرول أكثر من اللازم:</strong></p></td><td style="vertical-align:top"><p><strong>أ. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>إذا كنت تشك أنك تعطى إيزوبيرول أكثر من المفروض أن تتلقاه، قد تواجه بعض الأعراض الجانبية المدرجة أدناه، يرجى اعلام طبيبك.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:679px"><tbody><tr><td style="vertical-align:top"><p>إذا<em> </em>استخدمت<em> </em>إيزوبيرول<em> </em>أكثر<em> </em>مما<em> </em>ينبغي<em> </em>فتكلم<em> </em>مع<em> </em>طبيبك<em> </em>أو<em> </em>الممرضة.<em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>إذا نسيت أن تأخذ إيزوبيرول</strong></p></td><td style="vertical-align:top"><p><strong>ب. </strong><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>تأخذ<em> </em>جرعة<em> </em>مضاعفة<em> </em>لتعويض<em> </em>الجرعة<em> </em>التي<em> </em>نسيتها.<em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>إذا توقفت عن أخذ إيزوبيرول</strong></p></td><td style="vertical-align:top"><p><strong>جـ.</strong></p></td></tr><tr><td style="vertical-align:top"><p>سيخبرك طبيبك عن طول مدة العلاج باستخدام إيزوبيرول. لا تقم بإيقاف علاجك مبكرا حيث قد تعود أعراض مرضك أو قد تتفاقم.</p><p>إذا<em> </em>كان<em> </em>لديك<em> </em>أي<em> </em>أسئلة<em> </em>إضافية<em> </em>حول<em> </em>استخدام<em> </em>هذا<em> </em>المنتج،<em> </em>فاسأل<em> </em>طبيبك،<em> </em>الممرضة<em> </em>أو<em> </em>أو<em> </em>مقدم<em> </em>الرعاية<em> </em>الصحية<em> </em>أو<em> </em>الصيدلي.<em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>إذا واجهتك أي من الأعراض التالية، توقف عن استخدام إيزوبيرول واعلم طبيبك فورا أو اتصل بقسم الطوارئ لدى أقرب مستشفى:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; تنفس الصفير الفجائي، انتفاخ في شفاهك، لسانك و الحلق أ و الجسم، طفح، الإغماء أو الصعوبة في البلع )تفاعل تحسسي شديد(.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; احمرار الجلد مع نفطات أ و التقشر .قد يكون هناك نفطات شديدة و نزيف في الشفاه، العيون، الفم، الأنف&nbsp; و الأعضاء التناسلية .قد تكون هذه &quot;متلازمة ستيفينز-جونسون &quot;أو&quot; تقشر الأنسجة المتموتة البشروية التسممي.&quot;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; اصفرار الجلد، البول الداكن و التعب و التي ق د تكون أعراض مشاكل متزامنة في الكبد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هذه الأعراض نادرة وقد تؤثر على ما يصل الى 1 من 1000 شخص.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كان لديك أي من هذه الأعراض فذلك يعني أن لديك حساسية خطيرة تجاه إيزوبيرول .قد تحتاج إلى عناية طبية طارئة أو الذهاب للمستشفى.</p><table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كجميع الادوية، قد يسبب إيزوبيرول أعراض جانبية، ولكن قد لا تحصل عند الجميع.</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تشمل الأعراض الجانبية الأخرى على:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; <strong>شائع )قد يؤثر على ما يصل الى </strong><strong>1</strong><strong> من </strong><strong>10</strong><strong> أشخاص:(</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; الصداع</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تأثيرات على معدتك أو الأمعاء :الإسهال، ألم البطن، الإمساك، الريح )الانتفاخ.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; الشعور بالمرض )الغثيان( أو أن تكون مريضا )تقيؤ.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تفاعلات مكان الحقن.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; سلائل حميدة في المعدة.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; <strong>غير شائع )قد يؤثر على ما يصل الى </strong><strong>1</strong><strong> من </strong><strong>100</strong><strong> شخص:(</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تورم الأقدام و الكاحلين.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; اضطرابات النوم )الأرق.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; الدوار، الشعور بالتنمّل مثل&quot; الدبابيس و الإبر&quot;، الشعور بالنعاس.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; الشعور بالدوران )الدوخة.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; مشاكل في البصر مثل عدم وضوح الرؤية.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; جفاف الفم.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تغيرات في تحاليل الدم التي تفحص كيف يعمل الكبد.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; طفح جلدي، طفح جلدي ذا نتوء )شرى( و حكة في الجلد. &nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; كسور في الورك، الرسغ أو العمود الفقري )إذا استخدم إيزوبيرول بجرعات عالية لمدة طويلة(. &nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; <strong>نادر )قد يؤثر على ما يصل الى </strong><strong>1</strong><strong> من </strong><strong>1000</strong><strong> شخص:(</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; مشاكل في الدم مثل انخفاض عد د خلايا البيضاء أو الصفائح الدموية .قد يؤدي هذا إلى ضعف أو كدمات أو يجعل الالتهابات أكثر احتمالاً.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp; مستويات منخفضة للصوديوم ف ي الدم .قد يؤدي هذا إلى ضعف و شعور بالمرض )تقيؤ( و تشنجات.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; شعور بالتهيج، الارتباك أو الاكتئاب.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تغيرات في التذوق.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; شعور بتنفس صفير مفاجئ أو ضيق في التنفس )تشنج قصبي.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; التهاب في الفم من الداخل.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; التهاب يدعى&quot; السلاق &quot;و الذي من الممكن أن يؤثر على الأمعاء وتسببه الفطريات.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - مشاكل ف ي الكبد، تشمل اليرقا ن&nbsp; و الذي يمك ن أ ن يؤدي إل ى إصفرار الجلد&nbsp; و لو ن بول داك ن والتع ب.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تساقط الشعر )ثعلبة(.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; طفح جلدي عند التعرض لأشعة الشمس.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; آلام المفاصل أو آلام العضلات.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; شعور عام بالتوعك و فقدان الطاقة</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; زيادة التعرق.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; <strong>نادر جدا )قد يؤثر على ما يصل الى </strong><strong>1</strong><strong> من </strong><strong>10000</strong><strong> شخص:(</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تغيرات في تعداد الدم تتضمن ندرة المحببات )نقص خلايا الدم البيضاء.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; العدوانية/الغضب.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; رؤية، احساس أو سماع أشياء غير موجودة )هلوسة.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; مشاكل شديدة في الكبد تؤدي إلى فشل الكبد و التهاب الدماغ.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; ظهور مفاجئ لطفح شدي د أو نفطات أو تقشر الجلد .قد يرتبط ذلك بحمى مرتفعة و آلام المفاصل )حمامى عديدة الأشكال، متلازمة ستيفينز-جونسون، تقشرالأنسجة المتموتة البشروية التسممي.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; ضعف عضلي.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; مشاكل شديدة في الكلى.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; تزايد حجم الثدي لدى الرجال.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&bull; <strong>غير معروف </strong>)لا يمك ن تقدير تكرارها م ن البيانا ت المتوفرة(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تتعالج بإيزوبيرول لمدة تزيد عن ثلاث شهور فإنه من المحتمل أن تهبط مستويات المغنيسيوم في دمك. يمكن أن يظهر انخفاض مستويات المغنيسيوم على شكل تعب أو تقلصات عضلية لاإرادية أو إرتباك أو تشنجات أو دوخة أو زيادة في ضربات القلب .إذا حصل لديك أي من هذه الأعراض، أخبر طبيبك فوراً.&nbsp; قد يؤدي ايضا انخفاض مستويات المغنيسيوم إلى انخفاض مستويات البوتاسيوم او الكالسيوم في الدم .قد يقرر طبيبك إجراء فحوصات دم بشكل دوري لمراقبة مستويات المغنيسيوم لديك.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; إلتهاب في الأمعاء )يؤدي إلى الإسهال.(</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; طفح جلدي، ربما مع ألم في المفاصل. &nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;قد يؤثر إيزوبيرول في حالات نادرة جدا على خلايا الدم البيضاء و التي تؤدي الى نقص في المناعة .إذا كان لديك التهاب مع أعراض شديدة مثل الحمى مع تدني <strong>حاد </strong>في الحالة العامة أو حم ى مع أعراض التهاب موضعي مثل ألم في الرقبة، الحلق أو الفم أو صعوبة في التبول، فقم باستشارة طبيبك في أقرب وقت ممكن حتى يتم استبعاد نقص خلايا الدم البيضاء )ندرة المحببات( عبر تحليل للدم .من المهم أن تعطي معلومات عن أدويتك في هذا الوقت.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا<em> </em>أصبحت<em> </em>إحدى<em> </em>الأعراض<em> </em>الجانبية<em> </em>خطيرة،<em> </em>أو<em> </em>إذا<em> </em>لاحظت<em> </em>أي<em> </em>أعراض<em> </em>جانبية<em> </em>غير<em> </em>مذكورة<em> </em>في<em> </em>النشرة،<em> </em>يرجى<em> </em>اعلام<em> </em>طبيبك،مقدم الرعاية الصحية أ و الصيدلي.<em> </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يحفظ بعيدا عن متناول و مرأى الأطفال.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تستخدم إيزوبيرول بعد تاريخ الانتهاء المذكور على الكرتونة أو القارورة .تاريخ الانتهاء يشير إلى آخر يوم لذلك الشهر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يحفظ على درجة حرارة لا تتعدى&deg; 30 م .يحف ظ في علبته الأصلية من أجل حمايته من الضوء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تستخدم إيزوبيرول إذا لاحظت أي عيب في المنتج و/أو علبته.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يجب عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية .اسأل الصيدلي عن طريقة التخلص من الأدوي ة الغير مطلوبة.</p><p dir="RTL">هذه الإجراءات ستساعد على حماية البيئة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة</strong><strong> </strong><strong>الفعالة</strong><strong>:</strong> كل قارورة تحتوي على 42.5 ملغم إيزوميبرازول صوديوم ما يعادل 40 ملغم إيزوميبرازول.</p><p dir="RTL"><strong>السواغ(ات):</strong> ايديتات ثنائي الصوديوم ثنائي الهيدرات، هيدروكسيد الصوديوم (لضبط درجة الحموضة (pH.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ب.<strong><em>كيف يبدو إيزوبيرول و ما هي محتويات العلبة:</em></strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">إيزوبيرول هو مسحوق محلول للحقن/للتشريب يحتوي على 40 ملغم إيزوميبرازول.</p><p dir="RTL">إيزوبيرول هو كتلة لونها أبيض لأصفر فاتح مجففة بالتجميد في قارورة زجاجية غير ملونة مغلقة بسدادة مطاطية وغطاء ألمنيوم فتح علوي<strong>.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يتم وضع قارورة واحدة في كرتونة مطبوعة مع اً مع النشرة الخاصة بها.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شركة جينسينتا الدوائية للصناعة و التجارة</p></td></tr><tr><td style="vertical-align:top"><p>İş Kuleleri, Levent Mah., Meltem Sok.&nbsp; No: 10 Kule: 2 Kat: 24 4. Levent</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اسطنبول /تركيا&nbsp; - Beşiktaş&nbsp; &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: 00 83 733.212.09+</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: 10 83 733.212.09+</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;info@ gensenta.com.tr :بريد إلكتروني</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>المُصنّع: </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">شركة جينسينتا الدوائية للصناعة و التجارة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سانايي شارع رقم : 13</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينيبوسنا، باهسيليفلر&ndash;اسطنبول /تركيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: 00 67 454 212 09+</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: 96 67 454 212 09+</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;info@gensenta.com.tr :بريد إلكتروني</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لأي<em> </em>معلومات<em> </em>عن<em> </em>هذا<em> </em>المنتج<em> </em>الطبي،<em> </em>يرجى<em> </em>التواصل<em> </em>مع<em> </em>الوكيل<em> </em>المحلي<em> </em>لحامل<em> </em>ترخيص<em> </em>التسويق:<em> </em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المملكة العربية السعودية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">مؤسسة الصالحية التجاري ة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ص.ب. 991 الرياض 11421</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: 6955 464 11 966+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: 2634 364 11 669+</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;www.salehiya.com :موقع ألكتروني</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تاريخ لاعتماد هذه النشرة هو 08/2020؛ رقم الاصدار: 04 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ESOPEROL 40 mg Powder for Solution for Injection/Infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains: 
 
Active Substance: 
Esomeprazole 	40 mg (as 42.5 mg esomeprazole sodium) 
 
Excipients: 
Disodium edetate dihydrate 	1.50 mg 
Sodium hydroxide 	q.s. to pH 9.0–11.0 
 
For full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection and infusion. 
White to light-yellow colored lyophilized powder. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ESOPEROL injection and infusion is indicated as an alternative to the oral therapy, when oral therapy is not possible.</p><p>&nbsp;</p><p><u>Adults:</u></p><p>&minus; In gastro-esophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux.</p><p>&minus; In healing of gastric ulcers associated with NSAID therapy.</p><p>&minus; In prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is indicated in short-term maintenance of hemostasis and prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.</p><p>&nbsp;</p><p><u>Children and adolescents aged 1-18 years:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastric antisecretory treatment when the oral medication is not possible, such as:</p><p>&minus; Gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology/duration and frequency of administration:</strong></p><p>&nbsp;</p><p>Adults</p><p><em>Gastric antisecretory treatment when the oral route is not possible: </em></p><p>Patients who cannot take oral medication may be treated parenterally with 20&ndash;40 mg ESOPEROL once daily. Patients with reflux esophagitis should be treated with 40 mg once daily. Patients treated symptomatically for reflux disease should be treated with 20 mg once daily. For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily. For prevention of gastric and duodenal ulcers associated with NSAID therapy, patients at risk should be treated with 20 mg once daily.</p><p>&nbsp;</p><p>Usually the intravenous treatment duration is short and transfer to oral treatment should be made as soon as possible.</p><p>&nbsp;</p><p><em>Maintaining short-term hemostasis and prevention of rebleeding of gastric and duodenal ulcers </em>Following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be administered as a bolus infusion over 30 minutes, followed by a continuous intravenous infusion of 8 mg/h given over 3 days (72 hours).</p><p>&nbsp;</p><p>The parenteral treatment period should be followed by 40mg esomeprazole tablet once daily oral acid-suppression therapy.</p><p>&nbsp;</p><p><strong>Method of administration: </strong></p><p>For preparation of reconstituted solution, see section 6.6.</p><p>&nbsp;</p><p><em>Injection </em></p><p>40 mg dose</p><p>5 ml of the reconstituted solution (8 mg/ml) should be given as an intravenous injection over a period of at least 3 minutes.</p><p>&nbsp;</p><p>20 mg dose</p><p>2.5 ml the reconstituted solution (8 mg/ml) should be given as an intravenous injection when given a 20 mg dosage, over a period of at least 3 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p><em>Infusion </em></p><p>40 mg dose</p><p>The reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes.</p><p>&nbsp;</p><p>20 mg dose</p><p>Half of the reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p><u>80 mg bolus dose</u></p><p>The reconstituted solution should be given as a continuous intravenous infusion over 30 minutes.</p><p>&nbsp;</p><p>8 mg/h dose</p><p>The reconstituted solution should be given as a continuous intravenous infusion over a period of 71.5 hours (calculated rate of infusion of 8 mg/h.).<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Additional information regarding special populations: </strong></p><p><strong>&nbsp;</strong></p><p><strong>Impaired renal function: </strong></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution. (See section 5.2.).</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Impaired hepatic function: </strong></p><p>GERD: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum daily dose of 20 mg should not be exceeded.</p><p>&nbsp;</p><p>Bleeding ulcers: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, following an initial bolus dose of 80 mg ESOPEROL for infusion, a continuous intravenous infusion dose of 4 mg/h for 71.5 hours may be administered (see section 5.2).</p><p>&nbsp;</p><p><strong>Pediatric population: </strong></p><p><strong>&nbsp;</strong></p><p><strong>Posology/frequency of administration and duration: </strong></p><p><strong>&nbsp;</strong></p><p>Children and adolescents aged 1-18 years:</p><p><em>Gastric antisecretory treatment when the oral route is not possible</em></p><p>Patients who cannot take oral medication may be treated parenterally once daily, as a part of a full treatment period for GERD (see doses in table below).</p><p>&nbsp;</p><p>Usually the intravenous treatment duration should be short and transfer to oral treatment should be made as soon as possible.</p><p>&nbsp;</p><p>Recommended intravenous doses of esomeprazole</p><table border="0" cellspacing="0" cellpadding="0" style="width:645px"><tbody><tr><td style="vertical-align:top"><p>Age group</p></td><td style="vertical-align:top"><p>Treatment of erosive reflux esophagitis</p></td><td style="vertical-align:top"><p>Symptomatic treatment of GERD</p></td></tr><tr><td style="vertical-align:top"><p>1-11 years</p></td><td style="vertical-align:top"><p>Weight &lt; 20 kg: once daily 10 mg</p><p>Weight &ge;20 kg: once daily 10 mg or 20mg</p></td><td><p>Once daily 10 mg</p></td></tr><tr><td style="vertical-align:top"><p>12-18 years</p></td><td style="vertical-align:top"><p>Once daily 40 mg</p></td><td style="vertical-align:top"><p>Once daily 20 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Method of administration: </strong></p><p>For preparation of reconstituted solution, see section 6.6.<strong> </strong></p><p><strong>&nbsp;</strong></p><p><em>Injection<strong> </strong></em></p><p>40 mg dose</p><p>5 ml of the reconstituted solution (8 mg/ml) should be given as an intravenous injection over a period of at least 3 minutes.<strong><em> </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>20 mg dose<strong><em> </em></strong></p><p>2.5 ml or half of the reconstituted solution (8 mg/ml) should be given as an intravenous injection when given a 20 mg dosage, over a period of at least 3 minutes. Any unused solution should be discarded.<strong><em> </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>10 mg dose<strong><em> </em></strong></p><p>1.25 ml of the reconstituted solution (8 mg/ml) should be given as an intravenous injection over a period of at least 3 minutes. Any unused solution should be discarded.<strong><em> </em></strong></p><p>&nbsp;</p><p><em>Infusion </em></p><p>40 mg dose<em> </em></p><p>The reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes.<em> </em></p><p>&nbsp;</p><p>20 mg dose<em> </em></p><p>Half of the reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p>10 mg dose</p><p>A quarter of the reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p><strong>Geriatric Population: </strong></p><p>Dose adjustment is not required in the elderly.<strong> </strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance esomeprazole or to other substituted benzimidazoles or to any of the excipients of this medicinal product. 
 
Esomeprazole should not be used concomitantly with drugs like nelfinavir or atazanavir (see section 4.5). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with ESOPEROL may alleviate symptoms and delay diagnosis.</p><p>&nbsp;</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>(see section 5.1).</p><p>&nbsp;</p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded.</p><p>&nbsp;</p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p>&nbsp;</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolized through CYP2C19 should be considered. An interaction is observed between clopidogrel and omeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>&nbsp;</p><p><u>Bone fracture:</u></p><p>Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE):</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping esomeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Hypomagnesaemia:</u></p><p>Severe symptomatic and asymptomatic hypomagnesaemia has been reported in patients treated with PPIs for at least three months, and in most cases for a year. Serious side effects include tetany, arrhythmias, and seizures. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p><u>Interactions with Investigations for Neuroendocrine Tumors:</u></p><p>Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should stop esomeprazole treatment at least 5 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.</p><p>&nbsp;</p><p>Results from studies in healthy subjects have shown a pharmacokinetic/pharmacodynamics interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%. In light of this data, concomitant use of esomeprazole and clopidogrel should be avoided (see section 4.5).</p><p>&nbsp;</p><p><em>Sodium warning:</em></p><p>This medicinal product contains less than 1 mmol (23 mg) sodium. No side effects are to be expected in this dosage range for sodium.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p><em>Effects of esomeprazole on the pharmacokinetics of other drugs: </em></p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic medicinal product monitoring of digoxin should then be reinforced.</p><p>&nbsp;</p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole metabolizing enzyme. Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam. This interaction is clinically irrelevant. Concomitant oral administration of 40 mg esomeprazole and phenytoin resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients, dose reduction was not necessary in this study.</p><p>&nbsp;</p><p>In a clinical study concomitant oral administration of 40 mg esomeprazole to warfarin-treated patients showed that, despite a slight elevation in the trough plasma concentration of the less potent R-isomer of warfarin, the coagulation times were within the accepted range. However, in post marketing researches performed with oral esomeprazole, few isolated cases of elevated INR (International Normalized Ratio) of clinical significance have been reported during concomitant treatment with warfarin. Close monitoring of warfarin plasma levels is recommended when initiating and ending treatment with warfarin or other coumarin derivatives.</p><p>&nbsp;</p><p>Results from studies in healthy subjects have shown a pharmacokinetic/pharmacodynamics interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.</p><p>&nbsp;</p><p>Results from a number of observational studies are inconsistent with regard to increased risk or no increased risk for CV thromboembolic events when clopidogrel is given together with a PPI.</p><p>&nbsp;</p><p>When clopidogrel was given together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study in healthy subjects there was a decreased exposure by almost 40% of the active metabolite of clopidogrel. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in the clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups, likely due to the concomitant administration of low dose ASA.</p><p>&nbsp;</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged.</p><p>&nbsp;</p><p>Esomeprazole and omeprazole both act as an inhibitor of CYP 2C19. Omeprazole, given in doses of 40 mg daily to healthy subjects in cross-over study, increased C<sub>max</sub> and AUC of cilostazol by 18% and 26%, respectively. C<sub>max</sub> and AUC of one of its active metabolites were increased by 29% and 69%, respectively.</p><p>&nbsp;</p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t<sub>1/2</sub>) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole.</p><p>&nbsp;</p><p>When given together with proton pump inhibitors, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p>&nbsp;</p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19. For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, C<sub>max</sub> and C<sub>min</sub>). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The coadministration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg qd without omeprazole 20 mg qd. Co-administration of omeprazole (40 mg once daily) reduced mean nelfinavir AUC, C<sub>max</sub> and C<sub>min </sub>and mean AUC, C<sub>max</sub> and C<sub>min</sub> for the pharmacologically active metabolite M8 was reduced by 75-92%.&nbsp;</p><p>&nbsp;</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg qd). Treatment with omeprazole 20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole. Due to the similar pharmacodynamics effects and with atazanavir and nelfinavir is contraindicated.&nbsp;</p><p>&nbsp;</p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p>&nbsp;</p><p><em>Effects of esomeprazole on the pharmacokinetics of other medicinal products:</em></p><p>Esomeprazole is metabolized by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 like voriconazole may result in more than doubling of the esomeprazole effect. A dose adjustment of esomeprazole was not required in either of these situations.</p><p>&nbsp;</p><p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&#39;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p>&nbsp;</p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p>&nbsp;</p><p>Concomitant oral administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.</p><p>&nbsp;</p><p>Concomitant oral administration of 40 mg esomeprazole and phenytoin resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p>&nbsp;</p><p>Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUC by 15% and 41%, respectively.</p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General advice</p><p>Pregnancy Category: B</p><p>&nbsp;</p><p><strong>Women of childbearing potential/Birth control (Contraception) </strong>No interaction with contraceptives is expected.</p><p>&nbsp;</p><p>Pregnancy</p><p>For esomeprazole, limited data on use of pregnancies are available. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/fetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised if it is necessary to prescribe to pregnant women.</p><p>&nbsp;</p><p>Lactation</p><p>It is unknown whether esomeprazole is excreted in human milk. No studies have been conducted on nursing mothers. ESOPEROL should not be used during breast-feeding.</p><p>&nbsp;</p><p>Fertility</p><p>Esomeprazole has no effect on the fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (uncommon) have been reported (see section 4.8). If affected patients should not drive or use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The undesirable effects of esomeprazole sodium are usually gastro-intestinal system related. The most commonly reported side effects are inflation, nausea, diarrhea, constipation and abdominal pain as well as headache and dizziness.</p><p><strong>&nbsp;</strong></p><p>b. Tabulated summary of adverse reactions</p><p>The following adverse drug reactions have been identified or suspected in the clinical trials program for esomeprazole administered orally or intravenously and post-marketing when administered orally.<strong> </strong></p><p>&nbsp;</p><p>The undesirable effects are listed below according frequency.</p><p>&nbsp;</p><p>Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1000 to &lt; 1/100), rare (&ge; 1/10000 to &lt; 1/1000) and very rare (&lt; 1/10000), not known (cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td></tr><tr><td><p>Rare:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Peripheral edema</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypernatremia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia (see section 4.4); severe hypomagnesaemia can correlate with hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paresthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhea, flatulence, nausea/vomiting, fundic gland polyps (benign)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Administration site reactions*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td><p>Very rare:</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hip, wrist and spine fracture (see section 4.4.)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td><p>Very rare:</p></td><td style="vertical-align:top"><p>Interstitial nephritis : in some patients, renal failure has been reported concomitantly</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Gynecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Malaise, increased sweating</p></td></tr></tbody></table><p>* Administration site reactions have mainly been observed in a study with high-dose exposure over 3 days (72 hours). In the non-clinical program for esomeprazole intravenous formulation there was no evidence of vaso-irritation but a slight tissue inflammatory reaction at the injection site after subcutaneous (paravenous) injection was noted. Non-clinical data showed that clinical tissue irritation is somewhat concentration-relevant.</p><p>&nbsp;</p><p>c. Description of selected adverse reactions Adults</p><p>The safety of intravenous esomeprazole is based on results from clinical trials conducted in four different populations including patients having symptomatic GERD with or without a history of erosive esophagitis ﴾n=199﴿, patients with erosive esophagitis ﴾n=160﴿, healthy subjects ﴾n=204﴿ and patients with bleeding gastric or duodenal ulcers ﴾n=375﴿.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Symptomatic GERD and Erosive Esophagitis Trials </em></p><p>The data described below reflect exposure to esomeprazole sodium for injection in 359 patients. Esomeprazole sodium for injection was studied only in actively‐controlled trials. The population was 18 to 77 years of age; 45% Male, 52% Caucasian, 17% Black, 3% Asian, 28% Other, and had either erosive reflux esophagitis ﴾44%﴿ or GERD ﴾56%﴿. Most patients received doses of either 20 or 40 mg either as an infusion or an injection. Adverse reactions occurring in &ge;1% of patients treated with intravenous esomeprazole ﴾n=359﴿ in clinical trials are listed below:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Adverse Reactions Occurring at an Incidence &ge; 1% in the Esomeprazole Group</p></td></tr><tr><td style="vertical-align:top"><p>Adverse Reactions</p></td><td style="vertical-align:top"><p>% of patients</p><p>Esomeprazole</p><p>Intravenous</p><p>﴾n=359﴿</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>10.9</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>10.3</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>6.4</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>5.8</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td style="vertical-align:top"><p>Mouth dry</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness/vertigo</p></td><td style="vertical-align:top"><p>2.8</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>1.1</p></td></tr></tbody></table><p>&nbsp;</p><p>Intravenous treatment with esomeprazole 20 and 40 mg‐administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of esomeprazole.</p><p>&nbsp;</p><p><em>Risk Reduction of Rebleeding of Gastric or Duodenal Ulcers in Adults </em></p><p>The data described below reflect exposure to esomeprazole sodium for injection in 375 patients. Esomeprazole sodium for injection was studied in a placebo‐controlled trial. Patients were randomized to receive esomeprazole sodium for injection ﴾n=375﴿ or placebo ﴾n=389﴿. The population was 18 to 98 years old; 68% Male, 87% Caucasian, 1% Black, 7% Asian, 4% other, who presented with endoscopically confirmed gastric or duodenal ulcer bleeding. Following endoscopic hemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for a total treatment duration of 72 hours. After the initial 72‐hour period, all patients received oral proton pump inhibitor ﴾PPI﴿ for 27 days.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:657px"><tbody><tr><td style="vertical-align:top"><p>Incidence (%) of Adverse Reactions that Occurred in Greater than 1% of Patients within 72 Hours after Start of Treatment<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><sup>1</sup> Incidence &ge;1% in the esomeprazole group and greater than placebo group safety population <sup>2</sup> Injection site reactions included erythema, swelling, inflammation, pruritus, phlebitis, thrombophlebitis and superficial phlebitis.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Number ﴾%﴿ of patients &nbsp;&nbsp; &nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Esomeprazole &nbsp;&nbsp;&nbsp;&nbsp; Placebo ﴾n=375﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﴾n=389﴿ </strong></p></td></tr><tr><td style="vertical-align:top"><p>Duodenal ulcer hemorrhage &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16 ﴾4.3%﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16 ﴾4.1%﴿</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction<sup>2</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16 ﴾4.3%﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 ﴾0.5%﴿</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13 ﴾3.5%﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11 ﴾2.8%﴿</p></td></tr><tr><td style="vertical-align:top"><p>Cough &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ﴾1.1%﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 ﴾0.3%﴿</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 ﴾1.1%﴿ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 ﴾0.8%﴿</p></td></tr></tbody></table><p>&nbsp;</p><p>With the exception of injection site reactions described above, intravenous treatment with esomeprazole administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of esomeprazole.</p><p>&nbsp;</p><p>d. Pediatric population</p><p>A randomized, open-label, multi-national study was conducted to evaluate the pharmacokinetics of repeated intravenous doses for 4 days of once daily esomeprazole in pediatric patients 0 to 18 years old (see section 5.2). A total of 57 patients (8 children in the age group 1&ndash;5 years) were included for safety evaluation. The safety results are consistent with the known safety profile of esomeprazole, and no new safety signals were identified.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>e. Other special populations Neonates 0 to 1 month of age</p><p>The safety and effectiveness of esomeprazole sodium for injection in neonates have not been established.</p><p>&nbsp;</p><p>Geriatric population</p><p>No overall differences in safety and efficacy were observed between the elderly and younger individuals, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions:</u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull;&nbsp; Toll free phone: 8002490000</p><p>&bull;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with overdose. The symptoms described in connection with an oral dose of 280 mg were gastrointestinal symptoms and weakness. Single oral doses of 80 mg esomeprazole and intravenous doses of 308 mg esomeprazole over 24 hours were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilized.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Proton pump inhibitors</p><p>ATC code: A02BC05</p><p>&nbsp;</p><p>Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.</p><p>&nbsp;</p><p><em>Mechanism of action: </em></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme</p><p>+&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +</p><p>H K -ATPase &ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p><em>&nbsp;</em></p><p><em>Effect on gastric acid secretion: </em></p><p>After 5 days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours respectively, in symptomatic GERD patients. The effect is similar irrespective of whether esomeprazole is administered orally or intravenously.</p><p>&nbsp;</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown after oral administration of esomeprazole.</p><p>&nbsp;</p><p>During intravenous administration of 80 mg esomeprazole as a bolus infusion over 30 minutes followed by a continuous intravenous infusion of 8 mg/h for 23.5 hours, intragastric pH above 4, and pH above 6 was maintained for a mean time of 21 hours and 11-13 hours, respectively, over 24 hours in healthy subjects.</p><p>&nbsp;</p><p><em>Therapeutic effects of acid inhibition:</em></p><p>Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78% of patients after 4 weeks, and in 93% after 8 weeks of oral treatment.</p><p>&nbsp;</p><p>In a randomized, double blind, placebo-controlled clinical study, 764 patients with endoscopically confirmed peptic ulcer bleeding were randomized to receive esomeprazole as infusion (n=375) or placebo (n=389). Following endoscopic hemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours. After the initial 72 hour period, all patients received open-label 40 mg oral esomeprazole for 27 days for acid suppression. The occurrence of rebleeding within 3 days was 5.9% in the esomeprazole IV treated group compared to 10.3% for the placebo group. At 7 and 30 days post-treatment, the occurrence of rebleeding in the esomeprazole treated versus the placebo treated group was 7.2% vs 12.9% (p=0,0096) and 7.7% vs 13.6% (p=0,0092) respectively.</p><p><em>&nbsp;</em></p><p><em>Other effects related to acid inhibition:</em></p><p>During treatment with antisecretory drugs, serum gastrin increases in response to the decreased acid secretion. Chromogranin A (CgA) also increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumors. Esomeprazole treatment should be stopped temporarily at least 5 days before CgA measurement.</p><p>&nbsp;</p><p>An increased number of ECL enterochromaffin-Iike cells (Enterochromaffin-Iike cells, ECL) possibly related to the increased serum gastrin levels, have been observed in some patients during long-term treatment with orally administered esomeprazole.</p><p>&nbsp;</p><p>During long-term oral treatment with antisecretory drugs, gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>&nbsp;</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>and, in hospitalized patients, possibly also <em>Clostridium difficile</em>.</p><p>&nbsp;</p><p><em>Comparative clinical studies: </em></p><p>In a five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 24 patients with symptoms of GERD. On day 5, intragastric pH was maintained above 4.0 for a mean of 15.3 h with esomeprazole, 13.3h with rabeprazole, 12.9 h with omeprazole, 12.7 h with lansoprazole, and 11.2 h with pantoprazole (p&lt;or =0.001 for differences between esomeprazole and all other comparators). Esomeprazole also provided a significantly higher percentage of patients with an intragastric pH greater than 4.0 relative to the other proton pump inhibitors (p&lt;0.05).</p><p>&nbsp;</p><p><em>Pediatric population: </em></p><p>Results from the pediatric studies show that 0.5 mg/kg and 1.0 mg/kg esomeprazole in &lt;1 month old and 1 to 11 month old infants, respectively, reduced the mean percentage of time with intraesophageal pH&lt;4 and were comparable to those observed in adult patients at the 20 mg esomeprazole doses. In addition 0.5mg/kg and 1.0 mg/kg esomeprazole treatment decreased the esophageal acid exposure in &lt;1 month old and 1 to 11 month old infants. The safety profile appeared to be similar to that seen in adults.</p><p>&nbsp;</p><p>In a study in pediatric GERD patients (&lt;1 to 17 years of age) receiving long-term PPI treatment, 61% of the children developed minor degrees of ECL cell hyperplasia with no known clinical significance and with no development of atrophic gastritis or carcinoid tumors.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption:</u></p><p>Absorption following injection/infusion is 100%.</p><p>&nbsp;</p><p><u>Distribution:</u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p>&nbsp;</p><p><u>Metabolism and Elimination:</u></p><p>Esomeprazole is completely metabolized by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p>&nbsp;</p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolizers.</p><p>&nbsp;</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once daily dosing. Total exposure (AUC) increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance, probably caused by inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p>&nbsp;</p><p>Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once daily administration.</p><p>&nbsp;</p><p>The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the feces. Less than 1% of the parent drug is found in urine.</p><p><em>&nbsp;</em></p><p>Characteristics in patients</p><p>Approximately 3% of the population lacks a functional CYP2C19 enzyme and are called poor metabolizers. In these individuals, the metabolism of esomeprazole is probably mainly catalyzed by</p><p>CYP3A4. After repeated once daily administration of 40 mg oral esomeprazole, the mean total exposure was approximately 100% higher in poor metabolizers than in subjects with a functional CYP2C19 enzyme (extensive metabolizers). Mean peak plasma concentrations were increased by about 60%. Similar differences have been seen for intravenous administration of esomeprazole. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71&ndash;80 years of age).</p><p>&nbsp;</p><p>Following a single oral dose of 40 mg esomeprazole the AUC is approximately 30% higher in females than in males. No gender difference is seen after repeated once daily oral administration. Similar differences have been observed for intravenous administration. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p>&nbsp;</p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the total exposure of esomeprazole. Therefore, a maximum dose of 20 mg should not be exceeded in GERD patients with severe dysfunction. For patients with bleeding ulcers and severe liver impairment, following an initial bolus dose of 80 mg, a maximum continuous intravenous infusion dose of 4 mg/h for 71.5 hours may be sufficient. Esomeprazole or its major metabolites do not show any tendency to accumulate with once daily dosing.</p><p>&nbsp;</p><p>Pediatric population</p><p>In a randomized, open-label, multi-national, repeated dose study, to evaluate esomeprazole pharmacokinetics, esomeprazole was given as a once daily 3 minute injection to 50 pediatric patients 0 to 18 years old.</p><p>&nbsp;</p><p>The esomeprazole exposure following a 0.5mg/kg intravenous administration to 0-1 month old patients* was lower than that observed with 1.0 mg/kg in 1-11 months of age, but similar to that observed with 10 mg in 1-5 years, 10 mg in 6-11 years and 20 mg in 12-18 years of age. The exposure level with these doses was higher than that observed with 20 mg but lower than that with 40 mg esomeprazole intravenous administration. The exposure to esomeprazole following intravenous administration of 1 mg/kg in 1-11 months old infants, 20 mg in 6-11 years old children and 40 mg in 12-18 years old adolescents was similar to that observed with intravenous administration of 40 mg esomeprazole in adults.&nbsp;</p><p>&nbsp;</p><p>Model based predictions indicate that C<sub>ss-max </sub>following intravenous administration of esomeprazole as a 10-minute, 20-minute and 30-minute infusions will be reduced by on average 37% to 49%, 54% to 66% and 61% to 72%, respectively, across all age and dose groups compared to when the dose is administered as a 3-minute injection.</p><p>&nbsp;</p><p>* A patient in the age group 0 up to 1 month was defined as a patient with a corrected age of &gt;32 complete weeks and &lt;44 complete weeks, where corrected age was the sum of the gestational age and the age after birth in complete weeks. A patient in the age group 1 to 11 months had a corrected age of 44 complete weeks.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical studies reveal no particular hazard for humans, based on studies of single and repeated dose toxicity, embryo-fetal toxicity and mutagenicity.</p><p>&nbsp;</p><p>Oral carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects are the result of sustained, pronounced hypergastrinemia secondary to reduced production of gastric acid, and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion. In the non-clinical program for esomeprazole intravenous formulation there was no evidence of vaso-irritation but a slight tissue inflammatory reaction at the injection site after subcutaneous (paravenous) injection was noted. See section 4.8.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium edetate dihydrate<strong><em> </em></strong></p><p>Sodium hydroxide<strong><em> </em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Degradation of reconstituted solution is highly dependent on pH and therefore should only be prepared with 0.9% sodium chloride for intravenous administration as stated in section 4.2. The solution ready for use should not be mixed with any other drug and should not be given together with any other drug in the same infusion</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
 
Shelf-life after reconstitution: 
Chemical and physical in-use stability has been demonstrated for 12 hours at 30°C. From a microbiological point of view, the product should be used immediately. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store ESOPEROL in the original package, in order to protect from light. Store at room temperature below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each carton contains one 5ml Type I colorless glass vial with a gray bromobutyl rubber stopper and sealed with aluminum flip-off cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>The reconstituted solution should be inspected visually for particulate matter and discoloration prior to administration. Only clear solution should be used. For single use only.</p><p>&nbsp;</p><p>For 20 mg dosage, the half of the prepared solution should be used. Any unused solution should be discarded.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Injection 40 mg:</u></em></p><p>A solution for injection (8 mg/ml) is prepared by adding 5 ml of 0.9% sodium chloride. The reconstituted solution for injection is clear and colorless to very slightly yellow.</p><p>&nbsp;</p><p><em><u>Infusion 40 mg:</u> </em></p><p>A solution for infusion is prepared by dissolving the content of one vial with esomeprazole 40 mg in up to 100 ml of 0.9% sodium chloride for intravenous use.</p><p>&nbsp;</p><p>The reconstituted solution for infusion is clear and colorless to very slightly yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gensenta İlaç Sanayi ve Ticaret A.Ş. 
İş Kuleleri, Levent Mah., Meltem Sok.  No: 10 Kule: 2 Kat: 24  
4. Levent, Beşiktaş – Istanbul/TURKEY 
Tel : +90.212.337 38 00 Fax : +90.212.337 38 01 e-mail : info@gensenta.com.tr 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>